Molecular Insight Pharmaceuticals, which is developing innovative molecular imaging pharmaceuticals and targeted radiotherapeutics, filed the terms for its IPO on Friday. The Cambridge, MA-based company plans to offer 5 million shares at a range of $14-$16. RBC Capital Markets and Jefferies & Company are managing the deal, which has a proposed market cap of $400 million. Timing has yet to be announced.
